30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) clinical trials

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

This study looked at a new treatment called Lutathera for advanced bowel and stomach neuroendocrine tumours (NETs). It compared Lutathera plus standard long-acting octreotide against a higher dose of octreotide alone, to see if it helped patients live longer without their cancer growing.